HealthWhat to look for when buying probiotics Probiotic supplements abound in health food stores these days. The science doesn’t back up many of the bold health claims, though, and there’s minimal federal oversight or quality control of the products, which contain live bacteria meant to supplement or alter the microbial community already present in your gut.Read more: Probiotics make bold health claims, but the science is shakyDoctors say there’s no proven medical reason for most people to take probiotic supplements. But they’re unlikely to cause any harm. If you do want to give them a try, here are some tips to make sure you’re getting what you expect:The bacteria should be present in adequate amounts, which means billions of CFUs, or colony-forming units. The human gut contains trillions of resident bacteria, so scientists estimate at least one billion probiotic organisms are needed to make an impact via the intestine. Tags dietary supplementsnutritionprobiotics The bacteria should confer a health benefit, backed up by human trials that showed the probiotics had a positive effect on a specific condition. A group of experts recently compiled the clinical evidence for 40 brand-name probiotic products in Canada, many of which are also sold in the United States. Check out their ratings for each product, Levels I-III, based on the strength of evidence for specific health conditions. Be wary of products sitting on a shelf or in high temperatures for long periods of time. If bacteria experience any moisture or heat, they’ll begin to grow, use up the resources around them, and die. “If you pick a product in a shop window in Texas in the middle of summer, good luck,” said Gregor Reid, director of the Canadian Research and Development Centre for Probiotics at the Lawson Health Research Institute. Megan Scudellari A variety of probiotic drinks, powders, and chocolates available at health food stores. Alissa Ambrose/STAT Keep in mind that certain individuals should not take probiotics. Those with bowel damage due to injury, surgery, chemotherapy, or severe infection should steer clear due to the risk that the bacteria could migrate out of the intestines and into the bloodstream, said Dr. Shira Doron, a physician and epidemiologist at Tufts Medical Center. Individuals with compromised immune systems should also be wary, she added, since the immune system is needed to keep gut bacteria in check. [email protected] The bacteria should be living. If they are dead or inactivated, they’re not probiotics. By Megan Scudellari Jan. 21, 2016 Reprints About the Author Reprints
CHICAGO — Strict rest may not be the best medicine for kids with concussions, a Canadian study found, challenging the idea that physical activity should be avoided until symptoms disappear.A month after their concussions, ongoing or worse symptoms were more common in children and teens who were inactive during the week following injury, compared with those who engaged in physical activity during that first week. Activity was mostly light exercise including walking and swimming.The results were similar even among those who early on had three or more concussion symptoms, which can include nausea, headaches, and confusion. Physical activity still seemed to reduce chances for lingering symptoms a month after the concussion.advertisement Patients in the study and their parents were asked about symptoms and physical activity at seven and 28 days after the concussionIn the early-activity group, 29 percent reported ongoing or worsening symptoms 28 days after concussions versus 40 percent of the group reporting no extra physical activity beyond daily living activities.Among kids who reported having three or more symptoms in that first week, those who engaged in early physical activity regardless of intensity were 25 percent less likely to have ongoing or worse symptoms at 28 days than the no-activity group.Zemek said more research is needed to determine the ideal timing and intensity of physical activity to recommend after a concussion “to provide the best balance between symptom resolution and safety.”Until there are clear answers, the editorial says doctors and parents “should use common sense about allowing limited physical activity as tolerated and be cautious about resting a previously active athlete for prolonged periods.”— Lindsey Tanner Nearly 2 million concussions each year in kids’ sports, play Carlos Osorio/AP In the LabStrict rest may not be best medicine for kids’ concussions Related: Related: The researchers surveyed about 2,400 kids aged 5 to 18 treated for concussions in nine emergency departments in Canada. Most were sports-related injuries and most kids had at least one concussion symptom in the first week.Results from the 2013-2015 study were published Tuesday in the Journal of the American Medical Association .Current guidelines recommend rest until symptoms disappear to avoid additional concussions, which can increase chances for permanent brain damage. But an editorial published with the study says that advice “has resulted in some athletes resting for weeks or months, at which point rest may be less helpful and perhaps even harmful.”The study authors say resuming physical activity may increase blood flow to the brain, while inactivity may deprive patients of not only that benefit but also the psychological benefits of activities they enjoy. “It’s still important to have caution in the immediate post-injury period,” said lead author Dr. Roger Zemek, an emergency medicine specialist at Children’s Hospital of Eastern Ontario. After a sports-related concussion, kids “should always be removed from play and not return that day.” By Associated Press Dec. 20, 2016 Reprints Why rest helps the brain recover from concussion Tags concussionsresearch To avoid re-injury, kids should generally be sidelined from the sport or activity that led to the concussion until a doctor clears them to return, he said. But the study results suggest they can resume sports or other physical activities sooner than previously thought, he said.advertisement Associated Press About the Author Reprints
GET STARTED NIH budget cuts will jeopardize America’s leadership in medical research About the Author Reprints By Ronald A. DePinho April 7, 2017 Reprints In the last 10 years, remarkable advances have been made in how we fight cancer, work that was made possible by our nation’s support of biomedical research, largely through the National Institutes of Health. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens the body’s own immune system. Immunotherapy drugs have produced stunning results for many people suffering from advanced cancer.Immunotherapy saved President Jimmy Carter’s life. After being diagnosed with advanced melanoma that had spread to his brain, he underwent a combination of immunotherapy and radiation treatment. What could have been a sad story of death within months has turned into a compelling story of survival with no signs of cancer. Lydia Polimeni/NIH What’s included? Politics Tags cancerpolicyresearch What is it? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Ronald A. DePinho @RonDePinho Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED Log In | Learn More STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What is it? STAT Health Tech is our new weekly guide to how tech is transforming health care and the life sciences. Sign up here to receive it in your inbox every Wednesday.Good morning. We’re thrilled to bring you the first edition of STAT Health Tech! Log In | Learn More [email protected] Tags Artificial IntelligenceHealth ITmedical technology @caseymross Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED By Rebecca Robbins and Casey Ross May 15, 2019 Reprints About the Authors Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED Health Tech Welcome to the first edition of the STAT Health Tech newsletter National Technology Correspondent Casey covers the use of artificial intelligence in medicine and its underlying questions of safety, fairness, and privacy. He is the co-author of the newsletter STAT Health Tech. Adobe What’s included? Casey Ross
By Casey Ross and Kate Sheridan June 20, 2019 Reprints National Technology Correspondent Casey covers the use of artificial intelligence in medicine and its underlying questions of safety, fairness, and privacy. He is the co-author of the newsletter STAT Health Tech. General Assignment Reporter Kate covers biotech startups and the venture capital firms that back them. About the Authors Reprints Health TechWebinar: Progress and pitfalls in the AI-aided search for novel drugs Casey Ross Kate Sheridan @sheridan_kate Artificial intelligence is changing how pharmaceutical companies operate, how they develop and study new treatments, and even what form those treatments take.Pharma companies are now pairing medicines with software — so-called digiceuticals powered by virtual reality and AI. Most of the world’s largest drug companies now have a technology officer in their C-suites. And AI is now being used to help find new drug targets, model diseases, and make clinical trials more efficient. The expanding use of AI poses new scientific and ethical questions about whether the technology is safe and effective, and whether it could be used, wittingly or unwittingly, to subvert regulatory controls and perpetuate bias in the development of new treatments. STAT national technology correspondent Casey Ross and general assignment reporter Kate Sheridan discuss all this and more.advertisement @caseymross Download slides here (PDF). You may view the webinar recording below. Progress and pitfalls in the AI-aided search for novel drugsVolume 90%Press shift question mark to access a list of keyboard shortcutsKeyboard ShortcutsEnabledDisabledPlay/PauseSPACEIncrease Volume↑Decrease Volume↓Seek Forward→Seek Backward←Captions On/OffcFullscreen/Exit FullscreenfMute/UnmutemSeek %0-9 facebook twitter Email Linkhttps://www.statnews.com/2019/06/20/webinar-progress-and-pitfalls-in-the-ai-aided-search-for-novel-drugs/?jwsource=clCopied EmbedCopiedLive00:0041:1841:18 [email protected] [email protected]
Tags drug pricinggovernment agenciesopioidspharmaceuticalspharmalittleSTAT+ What’s included? Ed Silverman Pharmalot Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED About the Author Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. What is it? [email protected] STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Log In | Learn More @Pharmalot Rise and shine, everyone, the middle of the week is already here. Time moves quickly, yes? Of course, this is good reason to hang in there, since the end of the week cannot be too far away. Besides, what are the alternatives? And do you really want to know? Meanwhile, we are digging in for another busy day of foraging. So time to get cracking. Hope you have a simply smashing day and conquer the world. Meanwhile, here are some tidbits. Good luck. …Drug makers saturated the country with 76 billion opioid pills from 2006 through 2012, the Washington Post writes, citing newly disclosed data from a Drug Enforcement Administration database released as part of the opioid litigation. Just six companies distributed 75% of the pills: McKesson (MCK), Walgreens (WBA), Cardinal Health (CAH), AmerisourceBergen (ABC), CVS (CVS), and Walmart (WMT). Three companies manufactured 88% of the opioids: SpecGx, a unit of Mallinckrodt (MNK); Actavis Pharma, which is now part of Teva Pharmaceuticals (TEVA); and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals (ENDP). Pharmalittle: Data show pharma saturated U.S. with opioids; Swiss extradite Chinese researcher Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. By Ed Silverman July 17, 2019 Reprints GET STARTED Alex Hogan/STAT
@damiangarde Does impeachment have a pharma angle? Who’s to blame for drug shortages? And why is Wall Street down on biotech?We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT Washington correspondent Nicholas Florko joins us to break down what the impeachment inquiry means for the congressional fight over drug prices and the fate of the FDA. Then, Dr. Ben Davies, a University of Pittsburgh urologist, calls in to discuss what happens when key drugs face dangerous shortages. Later, we dig into biotech’s rough third quarter and discuss how things might change before the year’s out. Finally, Davies sticks around for a lightning round, covering rosé, menswear, and mail-order erectile dysfunction pills.For more on what we talk about, here’s the latest on drug pricing legislation; here’s the news on the possible next FDA commissioner; here’s more on drug shortages; and here’s a preview of the coming quarter in biotech.advertisement Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. Adam Feuerstein About the Authors Reprints We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected] [email protected] National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. [email protected] The Readout LOUDListen: Congressional paralysis, drug shortages, & biotech’s foul mood Damian Garde Tags biotechnologydrug pricingpharmaceuticals Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected] By Damian Garde , Rebecca Robbins, and Adam Feuerstein Oct. 3, 2019 Reprints @adamfeuerstein